Ruthenium-based core-shell nanoparticles with exceptional in vitro biocompatibility

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F17%3APU128344" target="_blank" >RIV/00216305:26620/17:PU128344 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62156489:43210/17:43912620

Výsledek na webu

<a href="https://mendelnet.cz/artkey/mnt-201701-0092_Ruthenium-based-core-shell-nanoparticles-with-exceptional-in-vitro-biocompatibility.php?back=/magno/mnt/2017/mn1.php?secid=4" target="_blank" >https://mendelnet.cz/artkey/mnt-201701-0092_Ruthenium-based-core-shell-nanoparticles-with-exceptional-in-vitro-biocompatibility.php?back=/magno/mnt/2017/mn1.php?secid=4</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Ruthenium-based core-shell nanoparticles with exceptional in vitro biocompatibility

Popis výsledku v původním jazyce

The current study demonstrates design preparation and characterization of biocompatible hybrid ruthenium core-shell nanoparticles (RuNPs) coated with polyvinylpyrrolidone (PVP) and polyoxyethylene stearate (POES). The resulting RuNPs were loaded with doxorubicin, as model anticancer drug. Resulting complex has an exceptional stability in physiological conditions. The cytotoxic effects of the complex were tested using cell lines representing breast and ovarian cancers and neuroblastoma. Although bare RuNPs had only negligible cytotoxicity, RuPDox caused an enhancement of doxorubicin cytotoxicity when compared to free doxorubicin. RuPDox promoted significantly increased stability of doxorubicin in human plasma and pronounced hemocompatibility assayed on human red blood cells. Results demonstrate that biocompatible RuNPs could have a great potential as versatile nanoplatform to enhance efficiency of anticancer therapy.

Název v anglickém jazyce

Ruthenium-based core-shell nanoparticles with exceptional in vitro biocompatibility

Popis výsledku anglicky

The current study demonstrates design preparation and characterization of biocompatible hybrid ruthenium core-shell nanoparticles (RuNPs) coated with polyvinylpyrrolidone (PVP) and polyoxyethylene stearate (POES). The resulting RuNPs were loaded with doxorubicin, as model anticancer drug. Resulting complex has an exceptional stability in physiological conditions. The cytotoxic effects of the complex were tested using cell lines representing breast and ovarian cancers and neuroblastoma. Although bare RuNPs had only negligible cytotoxicity, RuPDox caused an enhancement of doxorubicin cytotoxicity when compared to free doxorubicin. RuPDox promoted significantly increased stability of doxorubicin in human plasma and pronounced hemocompatibility assayed on human red blood cells. Results demonstrate that biocompatible RuNPs could have a great potential as versatile nanoplatform to enhance efficiency of anticancer therapy.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

10403 - Physical chemistry

Projekt

<a href="/cs/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

MendelNet 2017

ISBN

978-80-7509-529-9

ISSN

—

e-ISSN

—

Počet stran výsledku

6

Strana od-do

837-842

Název nakladatele

Mendel University in Brno

Místo vydání

Neuveden

Místo konání akce

Brno

Datum konání akce

8. 11. 2017

Typ akce podle státní příslušnosti

CST - Celostátní akce

Kód UT WoS článku

000440194500150